Aker BioMarine Launches New Delivery Platform to Improve Ingredient Bioavailability
11.09.22
The company has developed a phospholipid-based emulsifier to boost absorption rates severalfold.
Aker BioMarine has launched a new delivery platform, PL+, which can utilize phospholipids from krill oil as an emulsifier to maximize surface area and improve absorption of low-solubility and low-permeable substances.
Phospholipids (PLs) can be combined with ingredients like curcumin, CoQ10, CBD, lutein, and others to boost and enhance the uptake of these nutrients for cost-effectiveness and efficacy.
“We believe PL+ is a real industry gamechanger for the nutraceuticals industry,” said Matts Johansen, CEO of Aker BioMarine. “Since our debut into the supplements industry over 15 years ago, we knew we had a special ingredient with krill due to its phospholipid advantage, and for years we have investigated the true potential of PL’s and are excited to bring this new technology platform to life.”
“We take vitamins and supplements to support our overall health or compensate the lack of certain nutrients in our diet, but the absorption of some of these supplements is inconsistent, leading consumers to drop products because they are not seeing or feeling the key health benefits,” said Simon Seward, EVP for human health and nutrition. “By capitalizing on what we already know about krill and phospholipids and expanding our reach to new areas, we are helping to create endless opportunities within the nutra industry. In fact, with PL+, we are creating supplements with improved absorption, reduced formulation costs and enhanced product quality, key attributes needed to help our customers meet their consumers’ needs.”
PL+ is sourced from Aker BioMarine’s eco-harvesting technology onboard its fishing vessels. The phospholipids are extracted and concentrated in the company’s Houston-based facility using Flexitech, a patented technology process. The late stage of PL+ technology consists of removing non-polar lipids and adding the supplements. Aker BioMarine’s Houston facility is currently producing EPA and DHA fish oil, and anticipates the production of curcumin, CoQ10, CBD, and lutein by the end of 2023.
These aforementioned bioactives have poor solubility in the gastrointestinal tract, and can be flushed out of the body without delivering beneficial activity. Phospholipids are soluble in both water and fat, and serve as a means of biocompatibility, as supported by multiple publications, the company reports.
Phospholipids (PLs) can be combined with ingredients like curcumin, CoQ10, CBD, lutein, and others to boost and enhance the uptake of these nutrients for cost-effectiveness and efficacy.
“We believe PL+ is a real industry gamechanger for the nutraceuticals industry,” said Matts Johansen, CEO of Aker BioMarine. “Since our debut into the supplements industry over 15 years ago, we knew we had a special ingredient with krill due to its phospholipid advantage, and for years we have investigated the true potential of PL’s and are excited to bring this new technology platform to life.”
“We take vitamins and supplements to support our overall health or compensate the lack of certain nutrients in our diet, but the absorption of some of these supplements is inconsistent, leading consumers to drop products because they are not seeing or feeling the key health benefits,” said Simon Seward, EVP for human health and nutrition. “By capitalizing on what we already know about krill and phospholipids and expanding our reach to new areas, we are helping to create endless opportunities within the nutra industry. In fact, with PL+, we are creating supplements with improved absorption, reduced formulation costs and enhanced product quality, key attributes needed to help our customers meet their consumers’ needs.”
PL+ is sourced from Aker BioMarine’s eco-harvesting technology onboard its fishing vessels. The phospholipids are extracted and concentrated in the company’s Houston-based facility using Flexitech, a patented technology process. The late stage of PL+ technology consists of removing non-polar lipids and adding the supplements. Aker BioMarine’s Houston facility is currently producing EPA and DHA fish oil, and anticipates the production of curcumin, CoQ10, CBD, and lutein by the end of 2023.
These aforementioned bioactives have poor solubility in the gastrointestinal tract, and can be flushed out of the body without delivering beneficial activity. Phospholipids are soluble in both water and fat, and serve as a means of biocompatibility, as supported by multiple publications, the company reports.
